Iovance Biotherapeutics posts Q3 loss of $0.05 per share, revenue up 80% and reaffirms 2026 guidance
Iovance Biotherapeutics reported a third‑quarter loss of five cents per share, better than the consensus estimate of a nine‑cent loss. Revenue rose 80.1% year over year to $121.5 million, driven by Amtagvi sales that exceeded $100 million in the United States. The company reaffirmed its full‑year 2026 revenue outlook of $410 million‑$420 million and said its cash runway now extends into 2029. Management highlighted an objective response rate of 24.6% in a lung‑cancer trial and a 59.1% response in a biomarker‑selected subgroup.
Why it matters
The narrower loss and strong revenue growth suggest improving profitability, which may support the company’s plan to fund operations through 2029 without additional financing. The reaffirmed revenue guidance signals that analysts can continue to model earnings based on the $410‑$420 million target, and the positive trial data could enhance the value of upcoming sBLA submissions.
Key facts
- 1Third‑quarter 2026 loss was five cents per share, versus a consensus estimate of a nine‑cent loss. tradingview.com
- 2Revenue increased 80.1% year over year to $121.5 million. tradingview.com
- 3U.S. Amtagvi sales were approximately $102 million, up 77% from the year‑ago quarter. tradingview.com
- 4Proleukin generated about $20 million globally. tradingview.com
- 5Gross margin, excluding depreciation and amortization, rose to roughly 60% from 56% in the prior quarter. tradingview.com
- 6Research and development expenses fell 34.4% year over year to $49.3 million. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.